Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

Northwestern University filed a patent infringement lawsuit this week against Moderna, alleging the Cambridge, Mass.-based drugmaker used patented vaccine-delivery technology developed by ...

2 strain, prompting the approval of updated versions of the Pfizer and Moderna vaccines targeting that particular strain, and the Novavax vaccine, targeting its parent strain, JN.1, for the 2024 ...

GSK says it owns seven patents that “provide the foundation” for Moderna’s messenger RNA vaccine portfolio, and is now suing the biotechnology company for infringement. At issue is the work ...

Studies have shown these vaccines to be effective, with the Pfizer, GSK, and Moderna vaccines preventing RSV pneumonia and bronchitis in more than 80 percent of participants. A recent study ...

MDV: Multidose vial; NA: Not available ... influenza vaccination campaign estimated that the total time to get a vaccine ready to be administered per patient was 87 s for MDVs and 49.71 s for ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other most promising gene editing stocks to buy according to hedge funds. The pharmaceutical ...